Redenlab Supporting Larimar Therapeutics in Phase 1 SAD Clinical Trial

Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.

Click here to learn more.

Related Post

  • Posted on 20 July, 2021
    Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma company. Redenlab...
    • Posted on 31 May, 2021
      Redenlab is supporting a new speech focussed consortium for ataxia. SpeechATAXIA is a multi-language, multi-national, multi-ataxia study measuring communication change....
      • Posted on 21 May, 2021
        Redenlab are proud to support an upcoming randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia run by Professor...